完全切除的极高危透明细胞肾细胞癌患者辅助依维莫司治疗:3期安慰剂对照SWOG S0931(EVEREST)试验结果
EVEREST是一项3期试验,比较肾切除术后中高危或极高危肾细胞癌患者接受辅助依维莫司或安慰剂的疗效。二次分析纳入699例透明细胞成分且极高危患者,依维莫司组无复发生存期较安慰剂组显著改善(HR 0.80,95%CI 0.65-0.99,p=0.041),总生存无显著获益(HR 0.85,95%CI 0.64-1.14,p=0.3),但不良事件导致停药率高。
要点
- 极高危透明细胞肾细胞癌辅助依维莫司较安慰剂显著改善无复发生存期(HR 0.80,95%CI 0.65-0.99,p=0.041)。
- 总生存无显著获益(HR 0.85,95%CI 0.64-1.14,p=0.3)。
- 依维莫司组仅47%(163/348)完成全部计划治疗,安慰剂组为64%(225/351)。
核心结论
- 在极高危复发风险的透明细胞肾细胞癌患者中,辅助依维莫司较安慰剂显著改善无复发生存期,但不良事件导致高停药率。
- 总生存的治疗HR与无复发生存期结果一致,但未达统计学显著。
- 作者认为,关注风险分层工具和/或生物标志物以尽量减少不太可能获益者的毒性风险,这些信息有助于设计未来高危肾细胞癌的辅助试验。
研究设计与样本
- EVEREST是一项3期安慰剂对照试验,肾切除术后中高危或极高危肾细胞癌患者随机接受辅助依维莫司或安慰剂。
- 本次二次分析纳入肾切除术后具有任何透明细胞成分且极高危疾病(定义为pT3a(3-4级)、pT3b-c(任何级别)、T4(任何级别)或淋巴结阳性状态(N+))的患者。
- 采用按体能状态分层的Cox回归模型比较治疗组间的无复发生存期和总生存期。
- 1499例患者中717例为透明细胞组织学且极高危疾病,699例符合入组标准,其中348例随机至依维莫司组,351例随机至安慰剂组。
主要发现
- 两组患者特征相似。
- 依维莫司组仅163/348(47%)患者按计划完成全部治疗,安慰剂组为225/351(64%)。
- 辅助依维莫司导致无复发生存期统计学显著改善(HR 0.80;95%CI 0.65-0.99,p=0.041)。
- 未观察到生存获益证据(HR 0.85;95%CI 0.64-1.14,p=0.3)。
临床怎么用
- 作者认为,在极高危复发风险的透明细胞肾细胞癌患者中,辅助依维莫司较安慰剂显著改善无复发生存期,但不良事件导致高停药率。
- 作者认为,总生存的治疗HR与无复发生存期结果一致,但未达统计学显著。
- 作者认为,关注风险分层工具和/或生物标志物以尽量减少不太可能获益者的毒性风险,这些信息有助于设计未来高危肾细胞癌的辅助试验。
局限性
- 原文标题及摘要中未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: EVEREST is a phase 3 trial in patients with renal cell cancer (RCC) at intermediate-high or very high risk of recurrence after nephrectomy who were randomized to receive adjuvant everolimus or placebo. Longer recurrence-free survival (RFS) was observed with everolimus (hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.72-1.00; p = 0.051), but the nominal significance level (p = 0.044) was not reached. To contextualize these results with positive phase 3 trials of adjuvant sunitinib and pembrolizumab, we conducted a secondary analysis in a similar population of EVEREST patients with very high-risk disease and clear cell histology. METHODS: Postnephrectomy patients with any clear cell component and very high-risk disease, defined as pT3a (grade 3-4), pT3b-c (any grade), T4 (any grade), or node-positive status (N+), were identified. A Cox regression model stratified by performance status was used to compare RFS and overall survival (OS) between the treatment arms. KEY FINDINGS AND LIMITATIONS: Of 1499 patients, 717 had clear cell histology and very high-risk disease; 699 met the eligibility criteria, of whom 348 were randomized to everolimus arm, and 351 to the placebo arm. Patient characteristics were similar between the arms. Only 163/348 (47%) patients in the everolimus arm completed all treatment as planned, versus 225/351 (64%) in the placebo arm. Adjuvant everolimus resulted in a statistically significant improvement in RFS (HR 0.80; 95%CI 0.65-0.99, p = 0.041). Evidence of a survival benefit was not seen (HR 0.85; 95%CI 0.64-1.14, p = 0.3) CONCLUSIONS AND CLINICAL IMPLICATIONS: In patients with clear cell RCC at very high-risk for recurrence, adjuvant everolimus resulted in significantly improved RFS compared to placebo but resulted in a high discontinuation rate due to adverse events. Although the treatment HR for OS was consistent with RFS findings, it did not reach statistical significance. With a focus on risk stratification tools and/or biomarkers to minimize toxicity risk in those not likely to benefit, this information can help inform the design of future adjuvant trials in high-risk RCC.
引用
- Lara PN, Tangen C, Heath EI, et al. Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. Eur Urol. 2024. PMID: 38811313. doi:10.1016/j.eururo.2024.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。